Financial results - HOMEOMED S.R.L.

Financial Summary - Homeomed S.r.l.
Unique identification code: 22706962
Registration number: J26/1985/2007
Nace: 8622
Sales - Ron
158.330
Net Profit - Ron
33.292
Employee
4
The most important financial indicators for the company Homeomed S.r.l. - Unique Identification Number 22706962: sales in 2023 was 158.330 euro, registering a net profit of 33.292 euro and having an average number of 4 employees. Firma isi desfasoara activitatea in domeniul Activitati de asistenta medicala specializata having the NACE code 8622.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Homeomed S.r.l.

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 61.585 53.974 74.197 94.563 122.330 141.902 131.146 123.163 126.234 158.330
Total Income - EUR 61.709 54.316 74.767 94.591 122.331 141.904 146.334 123.165 126.246 158.342
Total Expenses - EUR 41.908 32.545 52.765 72.718 88.575 106.482 101.941 73.166 82.705 123.896
Gross Profit/Loss - EUR 19.801 21.771 22.003 21.873 33.756 35.422 44.394 49.998 43.541 34.446
Net Profit/Loss - EUR 17.949 20.141 21.110 14.626 32.533 34.003 43.179 49.031 42.529 33.292
Employees 3 1 2 2 3 3 2 2 3 4
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 25.8%, from 126.234 euro in the year 2022, to 158.330 euro in 2023. The Net Profit decreased by -9.108 euro, from 42.529 euro in 2022, to 33.292 in the last year.

Check the financial reports for the company - Homeomed S.r.l.

Rating financiar

Financial Rating -
Homeomed S.r.l.

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Homeomed S.r.l.

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Homeomed S.r.l.

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Homeomed S.r.l.

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Homeomed S.r.l. - CUI 22706962

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 78.199 74.665 73.750 71.306 64.400 58.819 56.992 54.209 52.015 50.802
Current Assets 41.122 39.109 39.358 39.067 44.108 44.537 38.201 47.267 33.887 30.617
Inventories 0 0 0 390 430 421 413 0 0 0
Receivables 38.967 38.486 39.052 38.035 41.466 39.382 35.608 35.999 31.986 28.854
Cash 2.155 623 306 642 2.213 4.733 2.180 11.268 1.901 1.763
Shareholders Funds -26.933 -7.016 14.166 22.729 32.627 42.649 50.580 75.177 83.061 77.286
Social Capital 45 45 45 44 43 42 41 40 41 40
Debts 146.254 120.813 99.055 87.794 75.919 60.869 45.089 26.516 3.305 5.169
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "8622 - 8622"
CAEN Financial Year 8622
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 30.617 euro in 2023 which includes Inventories of 0 euro, Receivables of 28.854 euro and cash availability of 1.763 euro.
The company's Equity was valued at 77.286 euro, while total Liabilities amounted to 5.169 euro. Equity decreased by -5.524 euro, from 83.061 euro in 2022, to 77.286 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Homeomed S.r.l.

Comments - Homeomed S.r.l.

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.